Nie ma to znaczenia
Endocrinology (2022) 163(11)
Over the four-year period, the percentage of female patients with a semaglutide or tirzepatide prescription who also had PCOS increased from 4.6% in 2021 to 5.7% in 2025, representing a 23.9% relative increase
doi: 10.3389/fphar.2026.1785916 Received 12 January 2026 Revised 11 April 2026 Accepted 20 April 2026 Published 18 May 2026 Volume 17 - 2026 Edited by Mostafa Rateb, University of the West of Scotland, United Kingdom Reviewed by Saeed Mohammadi, University of Nizwa, Oman Ngozi Amaeze, Bell College, United Kingdom Updates Copyright 2026 Li, Xia, Wang, Xu and Li
Over 68 weeks, participants in the Semaglutide group experienced an average weight loss of 15.3 kg, compared to a 2.6 kg reduction in the placebo group
Recently, the first approval for a dual-receptor agonist marks an important step in this development